Lidocaine HCl Injection Recall Issued by Eugia US LLC
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Eugia US LLC is voluntarily recalling 168,300 vials of Lidocaine HCl Injection, USP 2% due to labeling that covers the barcode.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on July 9, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, drug.
What Happened
Eugia US LLC initiated a voluntary recall because the label wrap covers the barcode, making it hard to scan.
Which Products Are Affected
Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, NDC 55150-164-02. Affected lots are 3LC26029A (exp Feb-2029) and 3LC26031A (exp Mar-2029). A total of 168,300 vials were distributed US Nationwide.
What You Should Do
Consumers and healthcare providers should verify lot information against the recalled lots listed by the FDA.
Why This Matters
The Class III recall affects a widely distributed prescription drug product across the United States.
Source
FDA recall D-0552-2026 (https://www.fda.gov)
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (709 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to July 9, 2026.
Frequently Asked Questions
Common questions about this FDA recall.